OBJECTIVES: The objective of this study is to assess and compare the characteristics of patients taking orals or subcutaneously administered disease modifying therapies (DMTs) for the treatment of relapsing remitting multiple sclerosis (RRMS). METHODS: A large US administrative retrospective claims database was used to identify patients diagnosed with RRMS and were prescribed either orally or subcutaneously administered DMTs between January 2010 and December 2012 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan at least a year. Descriptive statistics and chi-square tests were performed on the data. RESULTS: There were a total of 3,216 patients on Orals and 10,507 on Subcutaneous DMTs during the study period. Of these, more than 70% of the patients in both groups were females (75.8% vs 75.0%, p=0.359). There is no significant difference in the mean age of two groups (46.62±10.27 vs 46.57±10.68 years, p=0.822). And, the majority of the patients were in the 40 to 65 years age group (71.5% vs 69.2%, p=0.030). Thirty four percent of the patients were from South region (34.4% vs 27.0%, p<0.001). More than half in both groups patients were on group coverage (58.2% vs 56.9%, p=0.201). The majority of the Subcutaneous patients prescriptions were on health plan formulary (32.9% vs 85.5%, p<0.001). There was no significant difference in the distribution of patients between the groups with mental health problems (56.0% vs 56.0%, p=0.851). The great majority of the patients were received ≤30 days’ supply of DMTs in both the groups (93.2% vs 93.6%, p=0.022). In both groups, patients enrolled in the health plan for similar number of years (4.59±2.48 vs 4.55±2.49, p=0.473).  CONCLUSIONS: There is no much difference in the characteristics of patients between the two groups. It shows that the populations that take these DMTs are similar.